Style | Citing Format |
---|---|
MLA | Seyedtaghia MR, et al.. "Exome Sequencing in 9 Iranian Patients Expands the Mutational and Clinical Spectrum of Bardet–Biedl Syndrome." Biochemical Genetics, vol. , no. , 2025, pp. -. |
APA | Seyedtaghia MR, Habibi M, Hashemigorji F, Tehranifateh S, Moghimi P, Golestanifar A, Ghasemi MR, Sadeghi H, Mirfakhraie R, Mousavi P, Miryounesi M, Salehpour S (2025). Exome Sequencing in 9 Iranian Patients Expands the Mutational and Clinical Spectrum of Bardet–Biedl Syndrome. Biochemical Genetics, (), -. |
Chicago | Seyedtaghia MR, Habibi M, Hashemigorji F, Tehranifateh S, Moghimi P, Golestanifar A, Ghasemi MR, et al.. "Exome Sequencing in 9 Iranian Patients Expands the Mutational and Clinical Spectrum of Bardet–Biedl Syndrome." Biochemical Genetics , no. (2025): -. |
Harvard | Seyedtaghia MR et al. (2025) 'Exome Sequencing in 9 Iranian Patients Expands the Mutational and Clinical Spectrum of Bardet–Biedl Syndrome', Biochemical Genetics, (), pp. -. |
Vancouver | Seyedtaghia MR, Habibi M, Hashemigorji F, Tehranifateh S, Moghimi P, Golestanifar A, et al.. Exome Sequencing in 9 Iranian Patients Expands the Mutational and Clinical Spectrum of Bardet–Biedl Syndrome. Biochemical Genetics. 2025;():-. |
BibTex | @article{ author = {Seyedtaghia MR and Habibi M and Hashemigorji F and Tehranifateh S and Moghimi P and Golestanifar A and Ghasemi MR and Sadeghi H and Mirfakhraie R and Mousavi P and Miryounesi M and Salehpour S}, title = {Exome Sequencing in 9 Iranian Patients Expands the Mutational and Clinical Spectrum of Bardet–Biedl Syndrome}, journal = {Biochemical Genetics}, volume = {}, number = {}, pages = {-}, year = {2025} } |
RIS | TY - JOUR AU - Seyedtaghia MR AU - Habibi M AU - Hashemigorji F AU - Tehranifateh S AU - Moghimi P AU - Golestanifar A AU - Ghasemi MR AU - Sadeghi H AU - Mirfakhraie R AU - Mousavi P AU - Miryounesi M AU - Salehpour S TI - Exome Sequencing in 9 Iranian Patients Expands the Mutational and Clinical Spectrum of Bardet–Biedl Syndrome JO - Biochemical Genetics VL - IS - SP - EP - PY - 2025 ER - |